Biotech Stocks Under Scanner -- Biostage, Keryx Biopharma, Kite Pharma, and ZIOPHARM Oncology
NEW YORK, April 20, 2017 /PRNewswire/ --
For today, Stock-Callers.com redirects investors' attention to Biotechnology, an industry that focuses on novel drug development and clinical research aimed at treating diseases and medical conditions. Under evaluation this morning are: Biostage Inc. (NASDAQ: BSTG), Keryx Biopharmaceuticals Inc. (NASDAQ: KERX), Kite Pharma Inc. (NASDAQ: KITE), and ZIOPHARM Oncology Inc. (NASDAQ: ZIOP). You can access our complimentary research reports on these stocks now at:
http://stock-callers.com/registration
Biostage
Shares in Holliston, Massachusetts headquartered Biostage Inc. jumped 3.42%, ending Wednesday's trading session at $0.31. The stock recorded a trading volume of 547,727 shares. The Company's shares are trading 17.27% below their 50-day moving average. Moreover, shares of Biostage, which engages in developing bioengineered organ implants based on its Cellframe technology, have a Relative Strength Index (RSI) of 42.94.
On April 18th, 2017, Biostage announced that it has appointed Stephen F. Badylak DVM, PhD, MD to its Scientific Advisory Board. Dr. Badylak joins regenerative medicine and tissue engineering expert Dr. Joseph Vacanti as Co-Chairman. Visit us today and download your complete report on BSTG for free at:
http://stock-callers.com/registration/?symbol=BSTG
Keryx Biopharma
Boston, Massachusetts headquartered Keryx Biopharmaceuticals Inc.'s stock declined 1.21%, closing the day at $5.73 with a total trading volume of 553,720 shares. The Company's shares are trading 4.52% and 4.94% above their 50-day and 200-day moving averages, respectively. Shares of the Company, which focuses on providing medicines for patients with renal disease in the US, have an RSI of 51.58.
On April 18th, 2017, Keryx Biopharmaceuticals announced that it will host a conference call and webcast on Thursday, May 04th, 2017, at 8:00 a.m. ET to discuss its Q1 2017 financial results and provide corporate updates. The call will be webcast live with slides, and accessible under the Investors section of the Company's website for a period of 15 days after the call. The complimentary research report on KERX can be accessed at:
http://stock-callers.com/registration/?symbol=KERX
Kite Pharma
On Wednesday, shares in Santa Monica, California headquartered Kite Pharma Inc. recorded a trading volume of 965,329 shares. The stock ended the day 0.10% lower at $79.55. The Company's shares have advanced 67.19% in the previous three months and 77.41% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 11.60% and 40.12%, respectively. Furthermore, shares of Kite Pharma, which focuses on the development and commercialization of novel cancer immunotherapy products, have an RSI of 58.28.
On April 06th, 2017, Kite Pharma announced that it won the Clinical Trial Result of the Year award for ZUMA-1, its pivotal CAR-T trial of axicabtagene ciloleucel in patients with refractory aggressive B-cell non-Hodgkin lymphoma, at the Clinical and Research Excellence Awards. The award recognizes clinical achievements in the pharmaceutical industry and contribution to the advancement of therapies for unmet medical needs. Register for free on Stock-Callers.com and download the PDF research report on KITE at:
http://stock-callers.com/registration/?symbol=KITE
ZIOPHARM Oncology
Boston, Massachusetts headquartered ZIOPHARM Oncology Inc.'s stock rose 2.91%, finishing yesterday's session at $7.08 with a total trading volume of 806,448 shares. The Company's shares have advanced 13.46% in the last one month, 22.49% in the previous three months, and 32.34% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 8.96% and 20.03%, respectively. Additionally, shares of ZIOPHARM Oncology, which focuses on acquiring, developing, and commercializing a portfolio of cancer therapies that address unmet medical needs through synthetic immuno-oncology, have an RSI of 58.12.
On March 27th, 2017, ZIOPHARM Oncology announced the receipt of positive guidance from an End-of-Phase 2 meeting with the US FDA for its lead gene therapy product candidate, Ad-RTS-hIL-12 plus, orally administered veledimex, to harness and control IL-12 production for the investigational treatment of recurrent glioblastoma, an aggressive form of brain cancer with few treatment options. Get free access to your research report on ZIOP at:
http://stock-callers.com/registration/?symbol=ZIOP
--
Stock Callers:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
NO WARRANTY
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
http://stock-callers.com/legal-disclaimer/
CONTACT
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: [email protected]
Phone number: +44-330-808-3765
Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA
Share this article